Moderate to Severe Atopic Dermatitis Epidemiology Forecast 2026-2035

Moderate to severe atopic dermatitis represents a significant inflammatory burden, often requiring systemic therapy due to persistent symptoms and complications. According to Heng Chai et al., 2025, the global prevalence of atopic dermatitis is approximately 2.6%, affecting around 204.05 million individuals worldwide. According to the moderate to severe atopic dermatitis epidemiology forecast, rising disease severity continues to drive therapeutic demand.

Moderate to Severe Atopic Dermatitis Epidemiology Forecast Report Coverage

The analyst's “Moderate to Severe Atopic Dermatitis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of moderate to severe atopic dermatitis. It projects the future incidence and prevalence rates of moderate to severe atopic dermatitis cases across various populations. The study covers age, gender, and type as major determinants of the moderate to severe atopic dermatitis population. The report highlights patterns in the prevalence of moderate to severe atopic dermatitis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of moderate to severe atopic dermatitis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Moderate to Severe Atopic Dermatitis Understanding: Disease Overview

Moderate to severe atopic dermatitis is a chronic, relapsing inflammatory skin disorder characterized by intense pruritus, erythema, edema, and lichenification. It arises from a combination of epidermal barrier dysfunction, immune dysregulation, and genetic susceptibility, often involving mutations that affect skin integrity and heightened type 2 immune responses. Environmental triggers such as allergens, irritants, and microbial exposure further exacerbate the condition. The disease is commonly classified by severity (mild, moderate, and severe) based on lesion extent and symptom intensity, with moderate to severe forms showing widespread involvement, persistent inflammation, and a significant impact on quality of life.

Moderate to Severe Atopic Dermatitis Epidemiology Perspective

The moderate to severe atopic dermatitis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for moderate to severe atopic dermatitis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for moderate to severe atopic dermatitis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the National Eczema Association, more than 55% of adults with moderate to severe atopic dermatitis report inadequate disease control, with 86% experiencing daily itch and 63% reporting symptoms lasting at least 12 hours per day.
• As per the Pulmonology Advisor, the global point prevalence of atopic dermatitis is approximately 11.1% in children and adolescents and 6.3% in adults, indicating a substantial disease burden across populations with varying severity levels.
• According to Amy S. Paller et al., childhood atopic dermatitis is commonly diagnosed before age 5, with a global prevalence ranging from 3% to 20%, and is frequently associated with comorbid conditions such as asthma, allergic rhinitis, and food allergies.
• As per Patient Care Online, moderate disease affects 57.1% of patients and severe disease 32.5%, with higher severity observed among adolescents (36.9%) compared to younger children (28.2%), highlighting age-related differences in disease burden.
• According to the National Eczema Association, approximately 61% of adults with moderate to severe atopic dermatitis report skin pain, often described as burning or stinging, contributing significantly to morbidity despite low direct mortality rates.

Country-wise Moderate to Severe Atopic Dermatitis Epidemiology

The moderate to severe atopic dermatitis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the covered regions, the epidemiology of moderate to severe atopic dermatitis shows a substantial burden with notable geographic variation. In the United States, as per the National Eczema Association, approximately 16.5 million adults are affected, including 6.6 million with moderate to severe disease, while nearly 9.6 million children have atopic dermatitis, one-third of whom present moderate to severe forms. In the United Kingdom, France, and Italy, as per C Elise Kleyn et al., 2022, moderate cases account for 78-84% and severe cases 16-22% among identified patients, highlighting a consistently high disease burden across Europe, with emerging trends also observed in Germany, Spain, Japan, and India.

Moderate to Severe Atopic Dermatitis: Treatment Overview

Moderate to severe atopic dermatitis management focuses on controlling inflammation, restoring the skin barrier, and reducing flare frequency. First-line therapy includes regular use of emollients and topical anti-inflammatory agents such as corticosteroids and calcineurin inhibitors. For patients with an inadequate response, systemic therapies are introduced, including immunosuppressants like cyclosporine, methotrexate, or azathioprine. Targeted biologics such as dupilumab and Janus kinase inhibitors have significantly improved outcomes by modulating specific immune pathways. Adjunctive measures include phototherapy, infection control, and avoidance of triggers to maintain long-term disease stability.

Key Questions Answered

• What are the key findings of moderate to severe atopic dermatitis epidemiology in the 8 major markets?
• What will be the total number of patients with moderate to severe atopic dermatitis across the 8 major markets during the forecast period?
• What was the country-wise moderate to severe atopic dermatitis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of moderate to severe atopic dermatitis patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of moderate to severe atopic dermatitis during the forecast period of 2026-2035?
• What are the currently available treatments for moderate to severe atopic dermatitis?
• What are the risks, signs, symptoms, and unmet needs of moderate to severe atopic dermatitis?

Scope of the Moderate to Severe Atopic Dermatitis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of moderate to severe atopic dermatitis based on several factors.
• Moderate to Severe Atopic Dermatitis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The moderate to severe atopic dermatitis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.